Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with C...
Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection
About this item
Full title
Author / Creator
Ng, Teresa I , Pilot-Matias, Tami , Tripathi, Rakesh , Schnell, Gretja , Krishnan, Preethi , Reisch, Thomas , Beyer, Jill , Dekhtyar, Tatyana , Irvin, Michelle , Lu, Liangjun , Asatryan, Armen , Campbell, Andrew , Yao, Betty , Lovell, Sandra , Mensa, Federico , Lawitz, Eric J , Kort, Jens and Collins, Christine
Publisher
Switzerland: MDPI AG
Journal title
Language
English
Formats
Publication information
Publisher
Switzerland: MDPI AG
Subjects
More information
Scope and Contents
Contents
Glecaprevir (an NS3/4A protease inhibitor) and pibrentasvir (an NS5A inhibitor) are potent and pangenotypic hepatitis C virus (HCV) direct-acting antivirals. This report describes the baseline polymorphisms and treatment-emergent substitutions in NS3 or NS5A detected in samples from HCV genotype 1-infected patients receiving 3-day monotherapy of gl...
Alternative Titles
Full title
Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_270ad57d0b044800b8e572e7fac70c22
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_270ad57d0b044800b8e572e7fac70c22
Other Identifiers
ISSN
1999-4915
E-ISSN
1999-4915
DOI
10.3390/v10090462
